VanEck Biotech ETF
BBH
78 hedge funds and large institutions have $378M invested in VanEck Biotech ETF in 2015 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
74% more capital invested
Capital invested by funds: $217M → $378M (+$161M)
15% more funds holding
Funds holding: 68 → 78 (+10)
13.06% more ownership
Funds ownership: 35.66% → 48.72% (+13%)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
58% less call options, than puts
Call options by funds: $3.04M | Put options by funds: $7.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$55.7M |
| 2 |
Goldman Sachs
New York
|
+$53.3M |
| 3 |
VF
Virtu Financial
New York
|
+$15.3M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.67M |
| 5 |
Jane Street
New York
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.96M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.13M |
| 3 |
AP
Advisors Preferred
Rockville,
Maryland
|
-$2.39M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.93M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.8M |
BBH Hedge Fund Activity: Q1 2015 in Review
78 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2015, worth a combined $378M — up 74% from $217M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new BBH positions and 5 closed out — a net gain of 11 holders — while 23 added to existing stakes and 24 trimmed.
The largest buyer was Credit Suisse, adding an estimated $55.7M. The largest seller was Morgan Stanley, cutting an estimated $5.96M.
- 78 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2015, up from 68 in Q4 2014.
- Funds reported $378M of VanEck Biotech ETF stock for Q1 2015, up 74% quarter-over-quarter.
- 16 funds opened new VanEck Biotech ETF positions in Q1 2015 and 5 closed out, a net change of +11 holders.
- The largest VanEck Biotech ETF buyer in Q1 2015 was Credit Suisse, an estimated $55.7M added.
- The largest VanEck Biotech ETF seller in Q1 2015 was Morgan Stanley, an estimated $5.96M sold.
Based on aggregated 13F filings for Q1 2015.